# Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

> **NCT03461861** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 26 (actual)

## Conditions studied

- APOE 4

## Interventions

- **DRUG:** AGB101 220 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03461861
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03461861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03461861, "Network-Level Mechanisms for Preclinical Alzheimer's Disease Development". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03461861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*